The combination of ceralasertib and durvalumab, an anti-PD-L1 antibody, showed good activity and tolerable toxicity against melanoma [90], while it had failed against prior anti-PD-L1 drugs and advanced chemotherapy-refractory gastric cancer [91] in phase II clinical trials. The gene discussed is CD274; the disease is melanoma.